Recent results from a recent clinical trial indicate that a twice-yearly injection of Lenacapavir offers an overall 96% reduced risk of acquiring HIV. This makes Lenacapavir significantly more effective than the standard daily oral PrEP (pre-exposure prophylaxis).
